Guardant Health (GH) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
The meeting was called to order shortly after 9:30 A.M. Pacific Time and conducted virtually to maximize accessibility for stockholders.
The agenda and rules of conduct were made available on the meeting web portal, with procedures for voting and asking questions clearly outlined.
The formal portion of the meeting was conducted first, followed by a Q&A session for stockholders.
Board and executive committee updates
The Chairperson, Helmy Eltoukhy, presided over the meeting, with participation from the full Board of Directors and designated proxies.
Representatives from Deloitte & Touche LLP (auditors) and Gunderson Dettmer (legal counsel) were present.
Shareholder proposals
Four proposals were presented: election of Class II directors, ratification of the independent auditor, advisory approval of executive compensation, and advisory approval of the frequency of future votes on executive compensation.
Latest events from Guardant Health
- Rapid innovation and Shield adoption drive strong growth, targeting FCF breakeven by Q4 2027.GH
46th Annual William Blair Growth Stock Conference8 Jun 2026 - Record growth, new approvals, and guideline inclusion set stage for accelerated expansion.GH
Jefferies Global Healthcare Conference 20264 Jun 2026 - Q2 revenue up 31% year-over-year; 2025 guidance raised on strong growth and Shield FDA approval.GH
Q2 202529 May 2026 - Raised guidance on strong oncology and Shield growth, with AI and data driving future expansion.GH
Bank of America Global Healthcare Conference 202619 May 2026 - Revenue up 48% to $302M; guidance raised on strong oncology and screening growth.GH
Q1 20268 May 2026 - Record revenue growth, new product launches, and strong governance mark this year's proxy.GH
Proxy filing28 Apr 2026 - Key votes include director elections, auditor ratification, and annual say-on-pay advisory approval.GH
Proxy filing28 Apr 2026 - Quest partnership and CRC guideline updates drive growth, with Shield revenue set for strong gains.GH
Leerink Global Healthcare Conference 202626 Apr 2026 - Smart platform innovation and Shield’s multi-cancer expansion drive robust 2025 growth and 2026 outlook.GH
44th Annual J.P. Morgan Healthcare Conference22 Apr 2026